Navigation Links
Stem Cell Therapy Could Boost Kidney Transplant Success: Study
Date:3/20/2012

By Serena Gordon
HealthDay Reporter

TUESDAY, March 20 (HealthDay News) -- A novel technique that uses a kidney transplant recipient's own stem cells may someday replace or reduce the initial use of anti-rejection medications, new research suggests.

Six months after receiving a kidney transplant, only about 8 percent of people given their own mesenchymal stem cells experienced rejection compared with almost 22 percent of people on the standard anti-rejection drugs, according to the study.

"Mesenchymal stem cells are stem cells that can be differentiated into a variety of cells," explained Dr. Camillo Ricordi, study senior author and director of the Cell Transplant Center and Diabetes Research Institute at the University of Miami Miller School of Medicine.

"If you infuse mesenchymal stem cells at the time of the transplant, you could replace the use of powerful anti-rejection drugs, and maybe replace immunosuppressants altogether," he said. This technique could be used in the transplantation of islet cells (in the pancreas) for people with type 1 diabetes, and for other organ transplants, such as the liver, he added.

The people given their own stem cells also had improved kidney function earlier after transplant, Ricordi said.

Results of the study appear in the March 21 issue of the Journal of the American Medical Association.

One of the biggest remaining hurdles in organ transplantation remains the need for powerful anti-rejection and immune-suppressing medications after the transplant.

"Basically, the way we prevent kidney rejections is by putting you on very powerful anti-rejection drugs and immunosuppressive agents to prevent your cells from attacking the foreign organ," said Dr. Robert Provenzano, chair of the department of nephrology, hypertension and transplantation at St. John Providence Health System in Detroit. "But, the current standard has some problems, like an increased risk of infections and the possibility of creating a cancer."

The body's immune system sends out surveillance cells to protect the body against foreign invaders, such as a bacteria, virus or, in this case, a new organ, Provenzano said. The current method of preventing these cells from attacking the new organ is essentially to destroy the surveillance cells. But mesenchymal cells can naturally suppress those surveillance cells so they don't attack, he said.

To see if this suppression would be enough to prevent rejection, Ricordi and his colleagues, including researchers from Xiamen University in China, recruited 159 people with serious kidney disease who were on dialysis. They ranged in age from 18 to 61.

The study participants all had medically well-matched relatives willing to donate a kidney for transplant.

Each was randomly assigned to receive one of three treatments after transplant. One group got standard treatment with anti-rejection medication (induction therapy) and immune-suppressing medication known as calcineurin inhibitors (CNIs). Another group was infused with their own stem cells and the standard dose of CNIs, while the final group received stem cells plus a lower dose of CNIs (80 percent of the standard dose).

Survival rates for the patients and their new kidney were similar for all three groups at 13 to 30 months, the study found.

But before that, at six months, nearly 21.6 percent of those on standard therapy experienced rejection, compared with 7.5 percent of the stem cell plus standard CNIs, and 7.7 percent in the stem cell plus low-dose CNIs.

Both groups who received stem cells recovered kidney function faster than those on standard therapy. And at one year, the researchers found that the risk of opportunistic infections was reduced by nearly 60 percent in those who got the stem cell treatment.

Provenzano expressed enthusiasm for the new procedure. "I see this as the continued evolution of transplant medicine. It's very exciting to be able to use your own natural cells instead of more toxic medications," he said. He added that more studies are needed to confirm these findings and study long-term effects, but said "the data here appears promising."

Some experts are less impressed. "This is a novel technique, but I don't think it would be regarded as a significant step forward. It was only significant at six months," said Dr. Glyn Morgan, the associate director of transplantation at NYU Langone Medical Center in New York City. And, he added, "It's only a change in the induction protocol. Primary immunosuppressant agents are still used long term."

Other researchers have also been testing the use of stem cells in transplants. The March 7 issue of Science Translational Medicine reported on an attempt to transfer stem cells from the donor to the transplant recipient before transplant, in an attempt to create a hybrid immune system that would accept the new organ. Five of eight patients studied haven't needed medications to suppress their immune systems, according to the study.

Ricordi said perhaps a combination of stem cell therapies might lead to even more effective immune suppression.

More information

Learn more about the immune-suppressing medications used after a kidney transplant from the National Kidney Foundation.

SOURCES: Camillo Ricordi, M.D., director, Diabetes Research Institute, and chief, division of cellular transplantation, University of Miami Miller School of Medicine; Glyn Morgan, M.D., associate director of transplantation, NYU Langone Medical Center, and associate professor, NYU School of Medicine, New York City; Robert Provenzano, M.D., chair, department of nephrology, hypertension and transplantation, St. John Providence Health System, Detroit; March 21, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Explains How Shock Therapy Might Ease Severe Depression
2. Cytori breast reconstruction cell therapy trial results published
3. Study finds expensive procedure no more effective than medical therapy to prevent strokes
4. Estrogen-Only Therapy May Reduce Breast Cancer Risk
5. Internet-based therapy relieves persistent tinnitus
6. New universal platform for cancer immunotherapy developed by Penn-led team
7. A culprit behind brain tumor resistance to therapy
8. How chemotherapy becomes more effective
9. New approach to stroke therapy
10. Researchers find sarcoma tumor immune response with combination therapy
11. Web-Based Therapy May Help Teens With Chronic Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem Cell Therapy Could Boost Kidney Transplant Success: Study
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., the maker ... data center assets and audio-video devices has recently updated its Visio Stencils library ... free and download shapes and stencils from http://www.VisioStencils.com. , New devices ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... ... process in many scientific laboratories. The assembly protocols involve many repetitive steps and ... suited for automation, which enables the high-throughput needed, and results in a lower ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 ... report, which provides an exhaustive study of the U.S. ... nearly 242 companies are functional in this market ... With the leading companies, such as GlaxoSmithKline Plc., ... focusing aggressively on various marketing strategies to increase ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global lifestyle drugs market to grow ... The report, Global Lifestyle Drugs Market 2017-2021, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology: